1. Home
  2. CAC vs ABUS Comparison

CAC vs ABUS Comparison

Compare CAC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Camden National Corporation

CAC

Camden National Corporation

HOLD

Current Price

$53.97

Market Cap

876.2M

Sector

Finance

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.76

Market Cap

839.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAC
ABUS
Founded
1875
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
876.2M
839.5M
IPO Year
1996
2008

Fundamental Metrics

Financial Performance
Metric
CAC
ABUS
Price
$53.97
$4.76
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$47.00
$5.00
AVG Volume (30 Days)
101.7K
2.2M
Earning Date
04-28-2026
05-14-2026
Dividend Yield
3.51%
N/A
EPS Growth
6.08
55.26
EPS
1.29
0.87
Revenue
$41,739,000.00
$14,083,000.00
Revenue This Year
$19.15
N/A
Revenue Next Year
$6.05
$239.71
P/E Ratio
$41.83
$5.38
Revenue Growth
16.96
128.21
52 Week Low
$35.00
$3.08
52 Week High
$54.79
$5.10

Technical Indicators

Market Signals
Indicator
CAC
ABUS
Relative Strength Index (RSI) 66.69 66.90
Support Level $46.61 $4.15
Resistance Level N/A $4.85
Average True Range (ATR) 1.53 0.18
MACD 0.19 0.04
Stochastic Oscillator 85.06 91.98

Price Performance

Historical Comparison
CAC
ABUS

About CAC Camden National Corporation

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: